<DOC>
	<DOCNO>NCT00744042</DOCNO>
	<brief_summary>This clinical trial study safety efficacy asfotase alfa infant young child infantile onset HPP .</brief_summary>
	<brief_title>Safety Efficacy Study Asfotase Alfa Severely Affected Infants With Hypophosphatasia ( HPP )</brief_title>
	<detailed_description>Hypophosphatasia ( HPP ) life-threatening , genetic , ultra-rare metabolic disease characterize defective bone mineralization impair phosphate calcium regulation lead progressive damage multiple vital organ , include destruction deformity bone , profound muscle weakness , seizure , impair renal function , respiratory failure . There approve disease-modifying treatment patient disease . There also limit data available natural course disease time , particularly patient juvenile-onset form .</detailed_description>
	<mesh_term>Hypophosphatasia</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Legal guardian ( ) must provide informed consent prior study procedure Documented diagnosis severe HPP indicate : Total serum alkaline phosphatase least 3 standard deviation ( SD ) mean age Plasma pyridoxal 5'phosphate ( PLP ) least 4 time upper limit normal Radiographic evidence HPP ( hypophosphatasia ) , characterize : Flared frayed metaphyses Severe , generalize osteopenia Widened growth plat One HPPrelated finding : History presence : Nontraumatic postnatal fracture Delayed fracture heal History elevate serum calcium Functional craniosynostosis decrease head circumference growth Nephrocalcinosis Respiratory compromise Rachitic chest deformity and/or vitamin B6 dependent seizures Failure thrive Onset symptom prior 6 month age Age â‰¤ 36 month Otherwise medically stable ( patient may ventilatory support ) Legal guardian ( ) must willing comply study History sensitivity constituent study drug Current prior clinically significant cardiovascular , endocrinologic , hematologic , hepatic , immunologic , metabolic , infectious , urologic , pulmonary , neurologic , dermatologic , renal condition and/or major disease , opinion investigator , precludes study participation Treatment investigational drug within 1 month prior start study drug administration Current enrollment study involve investigational new drug , device treatment HPP ( e.g. , bone marrow transplantation ) Low serum calcium , phosphate 25 ( OH ) vitamin D Current evidence treatable form rickets Prior treatment bisphosphonate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hypophosphatasia</keyword>
	<keyword>HPP</keyword>
	<keyword>Bone Disease</keyword>
	<keyword>Soft Bones</keyword>
	<keyword>Low Alkaline Phosphatase</keyword>
	<keyword>genetic metabolic disorder</keyword>
	<keyword>alkaline phosphatase</keyword>
	<keyword>tissue non-specific alkaline phosphatase</keyword>
	<keyword>rickets</keyword>
	<keyword>osteomalacia</keyword>
</DOC>